Articles tagged with Vaccine Target
Researchers have developed a potential new approach against the highly drug-resistant hospital fungus Candida auris. A synthetic sugar molecule that corresponds to a component of the fungus's surface has been identified as a promising basis for a vaccine, protective antibodies, and a rapid diagnostic test.
Scientists at La Jolla Institute for Immunology have characterized human antibodies capable of neutralizing measles virus. The new panel of human antibodies may form the basis for future medical therapies against measles infection, with a study showing a 500-fold lower viral load in a rodent model.
A study of over 50,000 pregnant women in Norway found low vaccination rates against COVID-19 and influenza, with only 29.9% and 12.1% vaccinated respectively. The study highlights the need for targeted strategies to improve vaccination uptake among expectant mothers.
The new platform developed by UVA Health scientists can produce vaccines much faster, cheaper, and more easily than traditional approaches. The platform's proof-of-concept demonstrates its ability to produce highly immunogenic vaccines that can be manufactured at extremely low cost.
A cohort study found that most children received their first dose of MMR vaccine on time, but the proportion not receiving it by age 2 has increased. Children who missed early vaccinations were more likely to not receive any MMR vaccine by age 2.
The partnership aims to co-develop and evaluate next-generation self-amplifying RNA (saRNA) vaccines targeting seasonal and pandemic influenza. Apriori's Octavia platform will be combined with A*STAR IDL's saRNA delivery technology to develop improved H5 influenza vaccines that anticipate infection in humans.
Current PRRSV vaccines offer protection through a T cell response, rather than antibody production. Vaccination induces an immune response that identifies and attacks conserved parts of the virus.
The Phase 3 study demonstrated the safety and non-inferiority of EuTYPH-C Inj.® Multi-dose compared to a World Health Organization (WHO) prequalified comparator TCV, Typbar TCV®. The vaccine was shown to be well-tolerated across all age groups with no serious adverse events.
This book delves into the scientific foundations of mucosal vaccine platforms, discussing immunological mechanisms, novel adjuvants, and real-world development challenges. It serves as a valuable resource for professionals and students in life sciences, immunology, and pharmacology.
Researchers from The University of Osaka have identified a protein expressed on malaria-infected red blood cells that can hide from the immune system while also activating immune cells to destroy infected cells. This dual function makes the protein an excellent target for vaccine development and treatment.
Researchers identified six overexpressed and mutated tumor antigens strongly associated with poor prognosis in esophageal cancer. The study's findings suggest BTN2A1, MICA, and HHLA2 as promising targets for anti-ESCA mRNA vaccines.
A study by researchers at the University of Arizona Health Sciences found that vaccinated people generated an overall protective immune response to Delta and Omicron strains, with slightly fewer antibodies for the mutated parts of the virus. The research suggests that immune changes due to antigenic imprinting may not be a significant ...
The RSV protein subunit vaccine showed similar efficacy to clinical trials, with diminished immune response in immunocompromised patients. The vaccine was associated with a small increased risk of Guillain-Barré syndrome, but not immune thrombocytopenic purpura.
The BNT162b2 vaccine not only targets the COVID-19 virus but also helps reduce and control innate inflammation to other bacterial and fungal pathogens. By reprogramming innate immune cells, the vaccine reduces pro-inflammatory mediators, providing potential benefits beyond its primary target.
The European Centre for Disease Prevention and Control (ECDC) emphasizes the need for high immunization coverage to protect European populations from diseases like measles and polio. Vaccination remains a crucial tool in public health, with recent data showing a tenfold surge in reported measles cases in the EU/EEA.
Dr. Sabine Ehrt takes the helm of microbiology and immunology at Weill Cornell Medicine, aiming to build on the department's reputation in tuberculosis research and expand into other areas. She seeks to foster cross-disciplinary collaborations and boost junior faculty mentorship.
Cervical cancer cases worldwide reached 622,301 in 2022, with significant variations in age-standardized incidence rates across regions. Targeted prevention programs, especially HPV vaccination in low-income countries, are essential to reduce the global health burden.
Researchers have found that a specific protein modification to the immune protein MDA5 can block viral replication and reduce heart inflammation. The study's findings could lead to the development of broad-spectrum antiviral treatments that target multiple viruses.
The study found that influenza vaccination rates increased for Black and Hispanic older adults in rural areas, while decreasing for some white older adults. Determining the reasons behind these disparities is crucial for future research.
A promising new target for a Lyme disease vaccine has emerged: the Lyme bacterial protein CspZ. Genetic engineering revealed hidden regions that trigger a strong immune response. The modified protein promotes continuous production of protective antibodies, reducing the need for booster shots.
The MOPEVACLAS vaccine candidate is being tested in a Phase I clinical trial for its safety and immune response in humans. The vaccine targets Lassa fever, a hemorrhagic disease responsible for thousands of deaths worldwide each year.
The University of Texas at Arlington expert discusses the state's largest outbreak in 30 years, with fewer people getting vaccinated contributing to its spread. The MMR vaccine is 97% effective against measles and has been proven safe despite misconceptions about its safety.
Researchers found that mRNA-based COVID-19 vaccines cause persistent epigenetic changes in monocyte-derived macrophages, enabling a sustained immune response. These changes were preserved for six months after vaccination and required multiple doses to maintain long-term immunity.
Many teenagers enter adulthood with significant risk factors for cardiovascular disease, and emerging adulthood is a key time to address these risks. Interventions such as health practices, lifestyle changes, and improved access to healthcare can help reduce the risk of developing future cardiovascular disease.
A growing body of evidence suggests a significant link between human papillomavirus (HPV) and heart disease. Researchers pooled data from nearly 250,000 patients in seven studies, finding HPV-positive individuals had a 40% higher likelihood of developing cardiovascular disease.
Thomas Jefferson University has initiated a phase 1 clinical trial for a Lassa virus (LASV) vaccine, currently enrolling healthy volunteers. The vaccine's safety and immunogenicity will be assessed in both the rabies virus and LASV.
Researchers developed CeSPIACE, a 39-amino-acid peptide drug candidate that binds to the spike protein, blocking viral entry. It demonstrates strong binding to major SARS-CoV-2 variants and shows efficacy against multiple strains in vivo and in vitro experiments.
A cross-sectional study in Osaka City, Japan found a positive correlation between area deprivation, vaccination access, and female HPV vaccination. Higher socioeconomic status and medical facility access were associated with increased cumulative HPV vaccination uptake.
A recent study by Oregon Health & Science University and Weill Cornell Medicine has found that CMV lacking a certain viral protein complex can still be transmitted and cause significant harm to the developing fetus. The research suggests that additional vaccine targets need to be identified and explored to provide superior protection.
Researchers at the University of Leeds have developed a more affordable and lower-risk polio vaccine using virus-like particles (VLPs). VLPs mimic the outer protein shell of poliovirus but are empty inside, making them non-infectious yet capable of triggering an immune response.
A new Northwestern University study found that enhancing the brain's immune cells can clear Alzheimer's plaques and restore a healthier brain environment in immunized patient brains. The findings could reshape the future of Alzheimer's treatments by shifting the focus from removing plaques to harnessing the brain's natural defenses.
Researchers developed a nanoparticle that delivers an mRNA vaccine targeting a KRAS antigen, boosting the immune response against pancreatic cancer. Experiments in mice showed inhibited and prevented tumor growth, as well as long-term protection against recurrence.
A risk prediction model was developed to identify patients unlikely to complete HPV vaccination. The model uses patient demographics and clinical characteristics to guide targeted interventions, increasing vaccination rates among high-risk groups.
Researchers developed a new vaccine platform that provides robust, long-lasting protection against multiple flu strains and COVID-19. The vaccine boasts 100% survival rates in vaccinated mice following challenge with either virus.
The University of Texas at Arlington is joining forces with the Texas A&M Engineering Experiment Station to operate a new biomanufacturing center. This partnership will expand UTA's capabilities and provide access to financial support and industry partners, enabling researchers to develop and commercialize production of new bioprod...
Researchers at La Jolla Institute for Immunology have discovered a human antibody called mAb 3A6 that may prove useful against deadly outbreaks. The antibody was isolated from an Ebola survivor and found to block infection by binding to the viral stalk, offering protection at a very low dose.
Researchers discovered noncoding cryptic peptides as an alternative source of target antigens for ovarian cancer. The findings could improve treatment approaches by mobilizing the immune system to attack tumor cells.
Researchers have identified a new variant, clade 1b, of the mpox virus that has become more infectious and is spreading rapidly across borders. The study found that this variant primarily spreads through heterosexual contact in densely populated areas, with an estimated fatality rate of 3.4%.
A broadly neutralizing antibody has been shown to protect monkeys against severe H5N1 avian flu disease. The antibody's stable structure ensures it can withstand virus variants, providing universal protection against a globally spreading airborne infection. Serum levels of the antibody remained stable for up to 12 weeks.
Scientists at Tel Aviv University successfully transport mRNA-based drugs to the immune system of small and large intestines without passing through the liver. The breakthrough could enable treatments for inflammatory diseases such as Crohn's and colitis.
The foundation has awarded eight recipients of the 2025 Damon Runyon-Rachleff Innovation Award, including five early-career researchers with initial grants of $400,000 over two years. The awardees aim to develop novel cancer therapies using innovative approaches such as engineered skin bacteria and small molecule-boosted drug delivery.
A new study published in Nature reveals that tissue-resident memory CD8 T cells play unique roles based on their location within the small intestine, providing a local first line of defense against re-infection. The findings provide insight into how microenvironments and cellular interactions shape immune responses.
The COMBINE project focuses on the critical virus-cell binding step, aiming to identify key factors and potential therapeutic targets involved early in viral infections. The team will use a combination of pioneering approaches to develop novel inhibitors and vaccine candidates.
Dr. Blagosklonny's work introduced a new theory and promoted the use of rapamycin to slow aging and extend healthy life by targeting the mTOR pathway, leading to improved immune responses, heart protection, and potential cancer prevention.
Researchers at the University of São Paulo's Medical School have developed a COVID-19 vaccine using virus-like particles (VLPs), which proved highly protective, safe, and versatile in animal trials. The vaccine can be easily updated to combat variants of concern without requiring an adjuvant.
Researchers at the University of Gothenburg have discovered an antibody-like molecule, E10, that can protect mice from various influenza viruses. The molecule targets a conserved part of the virus's surface protein shared across multiple influenza types, providing effective protection against seasonal epidemics.
Researchers found that antibodies targeting a specific site on the malaria parasite's virulence protein bind to the human host's endothelial protein C receptor, neutralizing the parasite. The discovery provides new insights into prevention and treatment of severe malaria.
The American Heart Association has released its list of top cardiovascular research for 2024, focusing on prevention, treatment and the benefits of anti-obesity medications. The research highlights improvements in assessing cardiovascular risk, identifying early prevention opportunities and treating heart failure.
Researchers have discovered a monoclonal antibody capable of targeting multiple SARS-CoV-2 variants, including recent Omicron strains. K4-66's exceptional ability to adapt to the virus's frequent mutations makes it a promising candidate for vaccine and therapy development.
A new gold-based compound has been developed that slows tumour growth in animals by 82%, targeting cancers more selectively than standard chemotherapy drugs. It also blocks cancer cells' ability to form new blood vessels, a promising approach to reducing toxic side effects.
Researchers have discovered two human antibodies that can recognize and target proteins causing severe malaria. These broadly reactive antibodies may represent a common mechanism of acquired immunity to severe malaria, offering insights for the design of a PfEMP1-based vaccine or treatment targeting severe malaria. The breakthrough cou...
Argonne is using AI, high performance computing, simulation and structural biology to research novel ways to fight cancer and transform vaccine discovery. The lab aims to compress the drug discovery timeline and develop toolkits for broadly effective vaccines against multiple viral threats.
Researchers at MD Anderson Cancer Center have made significant advancements in understanding tissue regeneration, with a focus on epigenetic regulation and retrotransposon suppression. MicroRNAs have also been identified as potential biomarkers for COVID-19 severity in cancer patients, while a novel protein complex drives lung regenera...
New RSV vaccines have been found to be highly effective in preventing severe respiratory illness and hospitalizations, with an 80% efficacy rate. However, vaccination rates remain low, especially among older adults, highlighting the need for better understanding of risk factors and improved healthcare provider education.
Researchers have engineered probiotic bacteria to educate the immune system to destroy cancer cells, opening the door for a new class of cancer vaccines. The bacterial vaccine proved more efficacious than peptide-based therapeutic cancer vaccines in studies using mouse models of advanced colorectal and melanoma cancers.
A new clinical trial has found that the mpox vaccine is safe and generates an immune response equivalent to adults, providing hope for adolescents affected by the virus. The study's interim results were presented at IDWeek2024 conference in Los Angeles.
A new study explores Mpox clinical presentation, diagnostic approaches, and treatment strategies for patients with severe immunocompromised conditions. The study emphasizes the importance of supportive care and advanced therapeutics as first-line treatments.
A new study found that COVID-19 infection increased the risk of heart attack and stroke for up to three years after infection. The risk was higher among people with A, B or AB blood types compared to type O, according to researchers analyzing data in the UK Biobank.
Researchers at Houston Methodist are working on a national consortium to develop vaccines against two common and destructive strains of herpesviruses. The project aims to create prophylactic and therapeutic vaccines using a computational toolkit that could transform vaccine development.
Scientists at Houston Methodist will focus on developing efficacious vaccines and therapeutic antibodies for viruses in the Nairoviridae, Hantaviridae, and Paramyxoviridae families. The goal is to prepare for potential outbreaks and develop effective medical countermeasures in response to a next pandemic.